US-based investment firm T Rowe Price has announced its first exclusive distribution partnership with UBS GWM in Singapore and Hong Kong to offer the T Rowe Price Health Sciences Equity Strategy.
Under the partnership, the strategy will be available only through UBS GWM to private wealth clients in these markets.
Ziad Bakri, portfolio manager of the strategy, said: “The diverse and dynamic health sciences sector is amid a transformative period of innovation, creating significant investment opportunities across a broad array of companies in healthcare, pharmaceuticals and life sciences.
“A distinct focus of the strategy is companies which develop therapeutics for diseases that affect large patient populations and need improved treatment options, such as cancer, diabetes, and Alzheimer’s.”
Based in the firm’s headquarters in Baltimore, Bakri has 16 years of investment experience focused on analysis on key trends in the healthcare and biotech sectors, and was previously a medical practitioner. He is supported by an in-house research team with medical and scientific backgrounds.
Jansen Phee, head of fund investment solutions Apac at UBS GWM, said: “Healthcare is a key investment theme which offers diverse opportunities ranging from defensive compounders in the pharmaceutical area to emerging high growth companies involved in genetic therapies and health technology.
“The current environment further highlights the significance of healthcare as an important long-term theme.”
For more insight on asset and wealth management in Asia, please click on www.fundselectorasia.com
